"Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors" by N.H. Segal

Selected Works of Walter J. Urba, MD, PhD

Article

Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors

Annals of Oncology (2016)

N.H. Segal
J.R. Infante
R.E. Sanborn
G.T. Gibney
D.P. Lawrence
N. Rizvi
R. Leidner
T.F. Gajewski
E. Bertino
W.H. Sharfman
S. Cooley
S.L. Topalian
W.J. Urba
J.D. Wolchok
X. Gu
C. Passey
D. McDonald
P. Aanur
S. Srivastava
F.S. Hodi

Link

Disciplines

Medicine and Health Sciences and
Immunology and Infectious Disease

Publication Date

October 1, 2016

DOI

10.1093/annonc/mdw378.40

Citation Information

N.H. Segal, J.R. Infante, R.E. Sanborn, G.T. Gibney, et al.. "Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors" Annals of Oncology Vol. 27 (2016)
Available at: http://works.bepress.com/walter-urba/253/